Evidence map›Paper›PMID 31844591›Full record

ArticlePeerJ2019

Icaritin, an inhibitor of beta-site amyloid cleaving enzyme-1, inhibits secretion of amyloid precursor protein in APP-PS1-HEK293 cells by impeding the amyloidogenic pathway.

Fei Feng, Yuanyuan Li, Nanqu Huang, Yong Luo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Fei Feng *Department of Neurology, The First People's Hospital of Zunyi and Third Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Yuanyuan Li *National Drug Clinical Trial Institution, The First People's Hospital of Zunyi and Third Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Nanqu HuangNational Drug Clinical Trial Institution, The First People's Hospital of Zunyi and Third Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.ORCID 0000-0002-1910-6660
Yong LuoDepartment of Neurology, The First People's Hospital of Zunyi and Third Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.ORCID 0000-0002-1313-7423
Zunyi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIcaritin (ICT) is a prenylflavonoid derivative from

methodsWe exposed APP-PS1-HEK293 cells to ICT to investigate its effect on beta-site amyloid cleaving enzyme (BACE)1. Cell viability was evaluated by MTT and lactate dehydrogenase (LDH) assays. The half-maximal inhibitory concentration (IC

resultsIcaritin inhibited BACE1 activity and IC

conclusionsIcaritin, as a BACE1 inhibitor, inhibits APP secretion in APP-PS1-HEK293 cells by impeding the amyloidogenic pathway.

Indexed as

Alzheimer’s diseaseAmyloid precursor proteinAmyloid-β peptideBeta-site amyloid cleaving enzyme 1IcaritinPresenilin-1

Identifiers

PMID31844591
PMCPMC6910110
OpenAlexW2995502839

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.